Line 32: | Line 32: | ||
discussions, we concluded that the working with the mutated peptide would be more appropriate.<p> | discussions, we concluded that the working with the mutated peptide would be more appropriate.<p> | ||
− | <p>Dr.Ng.Iboyaima Singh felt that our delivery mechanism | + | <p>Dr.Ng.Iboyaima Singh felt that our delivery mechanism might not turn out to be cost effective while scaling up. He suggested that we look into active antimicrobial packaging as a viable alternative. However due to time constraints, we were unable to design and bring to life a suitable matrix system for immobilizing our peptide based on this idea. In the future, we plan to work on bringing to life an active packaging system using our peptide. </p> |
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
</div> | </div> |
Latest revision as of 17:04, 1 November 2017